The protective effect of royal jelly against cisplatin-induced renal oxidative stress in rats.
BACKGROUND
The aim of this study was to investigate the effects of royal jelly on cisplatin-induced nephrotoxicity and oxidative stress in rats.


METHODS
Adult male Wistar albino rats were randomly divided into eight groups: the control, cisplatin, royal jelly, and royal jelly plus cisplatin groups. Biochemical and histopathological methods were utilized for evaluation of the nephrotoxicity. Blood was collected and analyzed for blood urea nitrogen (BUN), alanine aminotransferase, aspartate aminotransferase, triglyceride, total cholesterol, uric acid, total bilirubin, and total protein levels. The kidney samples were stored for the measurement of malondialdehyde (MDA), glutathione peroxidase (GSHPx), superoxide dismutase (SOD), and catalase (CAT) activities and processed for histopathological examinations.


RESULTS
Administration of cisplatin to rats induced a marked renal failure, characterized with a significant increase in serum BUN and uric acid concentrations, and they had higher kidney MDA and lower GSH-Px, SOD, and CAT activities. In the groups that were administered RJ in association with CP, improvement was observed in some oxidative stress parameters and certain other biochemical parameters, pre-treatment with RJ being more effective.


CONCLUSIONS
The CP-induced changes in histopathologic findings of kidneys were partially reversed by treatment with royal jelly. The results provide further insight into the mechanisms of CP-induced nephrotoxicity and confirm the antioxidant potential of royal jelly.
Silici
Sibel
S
S. Cikrikcioglu Vocational College, Department of Animal Science, University of Erciyes, Kayseri, 38039, Turkey. silicis@erciyes.edu.tr
Ekmekcioglu
Oguz
O
Kanbur
Murat
M
Deniz
Kemal
K
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology*; D000975:Antioxidants / Q000627:therapeutic use; D001806:Blood Urea Nitrogen; D002374:Catalase / Q000378:metabolism; D002945:Cisplatin / Q000009:adverse effects / Q000494:pharmacology*; D005227:Fatty Acids / Q000627:therapeutic use*; D005979:Glutathione Peroxidase / Q000378:metabolism; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D023421:Models, Animal; D018384:Oxidative Stress / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D051437:Renal Insufficiency / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D013482:Superoxide Dismutase / Q000378:metabolism; D000099219:Royal Jelly
D000970:Antineoplastic Agents; D000975:Antioxidants; D002374:Catalase; D002945:Cisplatin; D005227:Fatty Acids; D005979:Glutathione Peroxidase; D008315:Malondialdehyde; D013482:Superoxide Dismutase; D000099219:Royal Jelly